866-997-4948(US-Canada Toll Free)

Metastatic Adenocarcinoma of The Pancreas - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Apr 2014

Category :

Oncology

No. of Pages : 113 Pages


This report provides comprehensive information on the therapeutic development for Metastatic Adenocarcinoma of The Pancreas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Adenocarcinoma of The Pancreas and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Adenocarcinoma of The Pancreas
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Metastatic Adenocarcinoma of The Pancreas and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Metastatic Adenocarcinoma of The Pancreas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Adenocarcinoma of The Pancreas pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Adenocarcinoma of The Pancreas
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Adenocarcinoma of The Pancreas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Metastatic Adenocarcinoma of The Pancreas Overview 8
Therapeutics Development 9
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Overview 9
Pipeline Products for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis 10
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Development by Companies 11
Metastatic Adenocarcinoma of The Pancreas - Therapeutics under Investigation by Universities/Institutes 14
Metastatic Adenocarcinoma of The Pancreas - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Metastatic Adenocarcinoma of The Pancreas - Products under Development by Companies 18
Metastatic Adenocarcinoma of The Pancreas - Products under Investigation by Universities/Institutes 19
Metastatic Adenocarcinoma of The Pancreas - Companies Involved in Therapeutics Development 20
Gilead Sciences, Inc. 20
MediGene AG 21
Nanotherapeutics, Inc. 22
Novartis AG 23
Aduro BioTech, Inc. 24
Halozyme Therapeutics, Inc. 25
Oncolytics Biotech Inc. 26
Peregrine Pharmaceuticals, Inc. 27
Threshold Pharmaceuticals, Inc. 28
Axcentua Pharmaceuticals AB 29
BioCancell Therapeutics, Inc. 30
NewLink Genetics Corporation 31
Eleison Pharmaceuticals, Inc. 32
Metastatic Adenocarcinoma of The Pancreas - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
glufosfamide - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
TH-302 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
MEK-162 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
pelareorep - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
BC-819 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
paclitaxel lipsomal - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Triapine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
luminespib - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
CRS-207 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
simtuzumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
PEGPH-20 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
AXP-10711 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
erismodegib - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
indoximod - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Stem Cell Therapy for Metastatic Adenocarcinomas - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
siG-12D LODER - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
PRI-724 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Anti-Angiogenesis Agent 2C3 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Metastatic Adenocarcinoma of The Pancreas - Recent Pipeline Updates 85
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects 110
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products 111

Appendix 112
Methodology 112
Coverage 112
Secondary Research 112
Primary Research 112
Expert Panel Validation 112
Contact Us 113
Disclaimer 113

List of Table


Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H1 2014 9
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Development by Companies, H1 2014 (Contd..1) 13
Number of Products under Investigation by Universities/Institutes, H1 2014 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Investigation by Universities/Institutes, H1 2014 19
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Gilead Sciences, Inc., H1 2014 20
Metastatic Adenocarcinoma of The Pancreas - Pipeline by MediGene AG, H1 2014 21
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Nanotherapeutics, Inc., H1 2014 22
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Novartis AG, H1 2014 23
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Aduro BioTech, Inc., H1 2014 24
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Halozyme Therapeutics, Inc., H1 2014 25
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Oncolytics Biotech Inc., H1 2014 26
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Peregrine Pharmaceuticals, Inc., H1 2014 27
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 28
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Axcentua Pharmaceuticals AB., H1 2014 29
Metastatic Adenocarcinoma of The Pancreas - Pipeline by BioCancell Therapeutics, Inc., H1 2014 30
Metastatic Adenocarcinoma of The Pancreas - Pipeline by NewLink Genetics Corporation., H1 2014 31
Metastatic Adenocarcinoma of The Pancreas - Pipeline by Eleison Pharmaceuticals, Inc., H1 2014 32
Assessment by Monotherapy Products, H1 2014 33
Number of Products by Stage and Target, H1 2014 36
Number of Products by Stage and Mechanism of Action, H1 2014 39
Number of Products by Stage and Route of Administration, H1 2014 41
Number of Products by Stage and Molecule Type, H1 2014 43
Metastatic Adenocarcinoma of The Pancreas Therapeutics - Recent Pipeline Updates, H1 2014 85
Metastatic Adenocarcinoma of The Pancreas - Dormant Projects, H1 2014 110
Metastatic Adenocarcinoma of The Pancreas - Discontinued Products, H1 2014 111

List of Chart


Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas, H1 2014 9
Number of Products under Development for Metastatic Adenocarcinoma of The Pancreas - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 16
Assessment by Monotherapy Products, H1 2014 33
Number of Products by Top 10 Target, H1 2014 34
Number of Products by Stage and Top 10 Target, H1 2014 35
Number of Products by Top 10 Mechanism of Action, H1 2014 37
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 38
Number of Products by Top 10 Route of Administration, H1 2014 40
Number of Products by Stage and Top 10 Route of Administration, H1 2014 41
Number of Products by Top 10 Molecule Type, H1 2014 42
Number of Products by Stage and Top 10 Molecule Type, H1 2014 43

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *